// App-Quantinova.ai

: The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.

Researchers

Presenter

  • Tatsuya Shimomura

Principal Investigators

  • Keiichiro Mori

  • Toshihiro Yamamoto

  • Hajime Onuma

  • Hiroyuki Inaba

  • Kenichi Hata

  • Takahiro Kimura

  • Shin Egawa

Medical Centers

  • The Jikei University School of Medicine, Tokyo, Japan

  • Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

Locations

  • Japan

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved